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Abstract
Background: Prior research has demonstrated that medication persistence (continued acquisition of therapy over
time) is far from optimal among patients with glaucoma. The purpose of the present study was to evaluate
persistence with prostaglandin analogs among glaucoma patients in the first therapy year using a modification of
a previously published technique.
Methods: This retrospective analysis of medical and pharmacy claims database included treatment-naive patients
dispensed bimatoprost, latanoprost, or travoprost between 1/1/04-12/31/04. “Index agent” was defined as the first
agent filled; “index date” was defined as the fill date. Follow-up continued for 358 days. Persistence measures for
first therapy year were: (1) whether last fill had sufficient days supply to achieve medication possession at year’s
end, and (2) number of days for which the index agent was available (days covered). Associations between index
agent and medication possession (logistic regression) and days covered (linear regression) were evaluated. Models
were adjusted for gender, age, and previous ocular hypertension diagnosis.
Results: 7873 patients met inclusion criteria (bimatoprost, n = 1464; latanoprost, n = 4994; travoprost, n = 1415).
Medication possession was 28% and days covered was 131 when using the unadjusted (pharmacy-reported) days
supply estimates and rose to 47-48% and days covered to 228-236 days when days supply was imputed.
Compared to latanoprost, odds of achieving medication possession at first year’s end were 26-34% lower for
bimatoprost and 34-36% lower for travoprost (p ≤ 0.001 for all comparisons). Days covered in the first year were
21-29 days lower for bimatoprost and 33-42 days lower for travoprost (p ≤ 0.001 for all comparisons). Failure to
refill the index agent within the initial 90 days was a strong predictor of poor persistence.
Conclusions: Persistence with ocular prostaglandin therapy remains a problem. Latanoprost users had greater
odds of achieving medication possession and had more days covered during the first therapy year.
Background
More than two million persons in the U.S. have open-
angle glaucoma [1]. Studies consistently report that
approximately half of patients with glaucoma have been
diagnosed or treated for the condition [2-4], and the
prevalence of ocular hypertension, which may precede
the onset of glaucoma, is considerably higher than that
of glaucoma [5-8].
Although it is intuitive that patients with chronic con-
ditions, such as glaucoma and hypertension, must take
medication continuously to receive the full benefit of
treatment, achieving persistence on pharmacotherapy
remains an important challenge [9-14]. For glaucoma
therapy, continued acquisition of medication over time,
or persistence, has been assessed by a number of meth-
ods, including the medication possession ratio [15-17]
and survival analysis [18-26]. The consensus of these
studies is that persistence is far from optimal for
patients receiving topical ocular hypotensive agents.
Greater efforts are clearly needed to improve persis-
tence for what is commonly an asymptomatic condition.
A recent study by Wilensky and associates [27] intro-
duced a methodological approach for measuring persis-
tence in glaucoma patients that used days supply as
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tence across prostaglandin analogues. In that study, the
reported days supply was adjusted upward, then
imputed with a conversion factor, to obtain a more rea-
listic estimate of days supply from the fill. The imputed
value of days supply for each fill was then used to assess
persistence at various points in time by calculating
whether the patient had sufficient medication on hand
given the days supply available from the last fill prior to
that day, and to estimate the number of days in the first
therapy year for which they had therapy coverage by
summing the imputed days supply for all fills in the first
year.
The current study replicated the potentially useful
technique developed by Wilensky and associates [27]
but with some adjustments to correct for a potential
selection bias. For instance, exclusion of early therapy
failures in related persistence studies has been criticised
for excluding patients who discontinued therapy for rea-
sons such as lack of efficacy or side effects [28].
Herein, we updated the time frame of the patient
selection period to 2004 and removed this controversial
step for excluding “early failures.” Using three alterna-
tive methods for imputing days supply from the pre-
scription claim, we evaluated two measures of
persistence in the first therapy year: (1) Medication Pos-
session at the End of Year (medication possession) and
(2) Days Covered in the First Therapy Year (days cov-
ered). (Note that the term “medication possession” is
analogous to the outcome of “persistence” used in
Wilensky and associates [27]. The term “days covered”
corresponds to the outcome of “adherence” in Wilensky
and associates [27].) We compare findings between
prostaglandin agents and provide summary estimates for
all agents combined.
Methods
Data were derived from the Ingenix LabRx administra-
tive claims database http://www.ingenix.com. This data-
base contains data from medical, hospital and pharmacy
claims that have been submitted to a large, single insur-
ance company. Patients included approximately 10 mil-
lion U.S. members annually across the U.S., with
membership in both commercial health maintenance
organisation and preferred provider organisation plans
as well as in Medicare-risk plans. The Ingenix database
was de-identified in accordance with Health Insurance
Portability and Accountability Act requirements prior to
being made available for analysis in this study; use of
these data in health research is exempt from Institu-
tional Review Board review [29]. Patients who had a
prescription dispensed for bimatoprost, latanoprost, or
travoprost from 1 January 2004 through 31 December
2004 were screened for inclusion. For each screened
patient, all available medical and pharmacy claims data
w e r ee x t r a c t e df o rt h et i m ep e r i o d1J a n u a r y2 0 0 3
through 31 December 2005.
Patients were excluded if they: (1) were less than 40
years of age on the index date; (2) were not continu-
ously enrolled for 180 days before and 358 days after
the index date; (3) had any topical ocular hypotensive
agent dispensed 180 days before the index date; (4) had
an ocular hypotensive other than the index agent dis-
pensed on the index date; and (5) had no diagnosis for a
glaucoma-related condition (International Classification
of Diseases, Ninth Revision [ICD-9] diagnosis = 365*) for
180 days before the index date. Having previous glau-
coma surgery was not a criterion for exclusion. The first
agent filled for eligible patients in 2004 was the index
therapy, and the date of this initial fill was the index
date. Prescription claims were followed for each eligible
patient for the first 358 days after the index date, the
end-of-year time point used by Wilensky and associates
[27].
To estimate persistence across all prostaglandins and
to compare individual agents, we adapted the approach
by Wilensky and associates [27]. First, medication pos-
session was defined dichotomously by whether the date
of the last fill of the index prostaglandin within the 358-
day follow-up period had sufficient days supply to have
medication on hand to achieve possession of medication
on day 358, the last day of the therapy year. Medication
possession was defined as a dichotomous indicator (yes/
no) depending on whether a given patient had medica-
tion on hand on the last day of the therapy year (day
358). For instance, to a subject who was dispensed a 30-
day supply, 20 days prior to year end (on day 338),
would be expected to have a “sufficient days supply” to
last through the end of the year (on day 358) and would
have a value of “yes” for medication possession. Sec-
ondly, we estimated the number of days in the first ther-
apy year for which there was available days supply (days
covered). This was done by summing the imputed days
supply for all index agent fills that occurred between the
index date through day 358. For patients who had a
summed days supply > 358, the value of days covered
was set as 358.
In calculating both measures, we employed three sepa-
rate imputation methods for days supply to address
uncertainty regarding the days supply available in a
given prescription fill of a study drug. Each claim
included an estimate of days supply as recorded by the
pharmacist at dispensing. When including days supply
in their study, Wilensky and associates [27] adjusted this
value upwards to control for a likely underestimation
bias by multiplying by a variable factor of 2.1 for bima-
toprost and 2.0 for latanoprost and travoprost. In the
current analysis, we applied the exact adjustment factors
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factor was estimated by dividing the mean number of
days (per mL) between all consecutive fills of each agent
by the reported days supply (per mL) reported on the
pharmacy claim. Thus, for bimatoprost, the mean days
between fills (per mL) was 15.8 days, whereas the
reported days supply (per mL) was 7.4 days. The ratio
of 15.8/7.4 or 2.1 was used to adjust the mean days sup-
ply of a 2.5 mL bimatoprost bottle from the value of
18.5 days reported on the claim to 38.9 days for analysis
in that study. We did not recalibrate these adjustment
factors with our claims data since the numerator of the
adjustment factor (days between fills) would presumably
lengthen for patients who were less persistent on a
given therapy, thus confounding the adjustment factor
with a proxy measure of the outcome being assessed.
To further explore the sensitivity of findings to esti-
mates of days supply we applied three alternative days
supply estimates: (1) “Unadjusted” as originally reported
on the claim by the pharmacist; (2) “2.0-2.1 Variable
Factor” used by Wilensky et al [27] as described above;
and (3) “2.0 Constant Factor for all study drugs with a
45-day minimum imputed days supply.” For the latter,
we chose to set 2.0 as a constant factor across agents
for simplicity and set the minimum days supply at 45
days across agents since this agreed with the empirical
work of Platt et al. [30], who examined days between
actual prostaglandin fills, and since Mick et al. [31] and
Fiscella et al. [32] reported in vitro expected days sup-
plies of 43 to 56 days across all agents and both studies.
For all analyses in this study, results are described sepa-
rately by replicating each of the three estimates of days
supply described above.
For all prostaglandins combined and each agent indi-
vidually, we estimated medication possession and days
covered for each patient. Frequency distributions of
patients achieving medication possession were reported
for each of the agents and evaluated with a chi-square
test of significance. Means were calculated for days cov-
ered by a prostaglandin agent, and tests of significance
used the F test.
To adjust for differences in characteristics among
patients receiving different agents, separate regression
models were created to adjust for key available factors.
For the dichotomous measure, medication possession,a
logistic regression model was developed using the inde-
pendent variables prostaglandin agent, gender, age cate-
g o r y( 4 0t o5 4y e a r s ,5 5t o6 4y e a r s ,6 5t o7 4y e a r s ,a n d
75 years and older), and diagnosis for ocular hyperten-
sion/borderline glaucoma during the 180 days prior to
and including the index date (ICD-9 = 365.00 [preglau-
coma], 365.01 [open-angle glaucoma with borderline
findings], or 365.04 [ocular hypertension]). For the con-
tinuous measure, days covered, a linear regression model
was developed with the same set of independent
variables.
To evaluate whether exclusion of early therapy failures
would have affected our findings, we replicated the uni-
variate analyses for our eligible patient cohort against
the smaller set of patients who would have remained
had this “early failures” exclusion rule been applied.
Results
Of 42 427 patients who had a prescription fill for one of
the index agents during 2004, 7873 were eligible and
were retained for analysis (Table 1). Table 2 shows dif-
ferences in patient characteristics among the treatment
cohorts. Prescriptions for bimatoprost, latanoprost, and
travoprost accounted for 1464, 4994, and 1415 patients,
respectively; 57% of patients were female, and this rate
was similar among therapies (p = 0.129). The mean age
and the distribution of patients by age categories dif-
fered by therapy (p ≤ 0.001 for both). Latanoprost users
were oldest (mean = 64 years) followed by those pre-
scribed bimatoprost (mean = 63 years) and then travo-
prost (mean = 62 years). Although all included subjects
were required to have a prior medical service coded for
glaucoma, we examined those who also had a service
coded for “ocular hypertension” (Table 2) in the pre-
vious six months as signal of a new or lower severity
glaucoma condition. A substantially larger proportion of
latanoprost users (44%) had an “ocular hypertension”
diagnosis during the 180-day preindex period followed
by users of travoprost (39%) and then bimatoprost (36%;
p < 0.001).
Table 1 Eligible subjects
Application of exclusion criteria to patient
population
Patient
count*
Initial population of patients who were
prescribed a prostaglandin ocular hypotensive
agent between 1/1/2004-12/31/2004 42 427
Patients < 40 years of age on index prescription
date 1682
Patients not having continuous enrollment for
180 days before and 358 days after index date 9595
Patients having another topical ocular
hypotensive dispensed 180 days before index
date (ie, not new to glaucoma therapy) 24 823
Patients not having monotherapy on index date
(ie, had more than one ocular hypotensive agent) 7662
Patients having no diagnosis for any glaucoma-
related condition (ICD-9 diagnosis = 365*)
for 180 days before index date 9791
Eligible patients for analysis 7873
*Many patients met criteria for more than one of the exclusion rules shown.
ICD-9 = International Classification of Diseases, Ninth Revision.
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only 28% when using the unadjusted days supply esti-
mate (Table 3). Levels rose to 47 and 48% when the
days supply estimates were adjusted with imputation
factors. Medication possession varied significantly (p ≤
0.001) by therapy. Medication possession was equivalent
or slightly higher for bimatoprost compared to travo-
prost. However, medication possession ranged from
seven to nine percentage points higher for latanoprost
than for bimatoprost across days supply imputations.
Similar findings were seen when days covered was the
outcome (Table 3). For all therapies, the number of days
Table 2 Patient characteristics
Bimatoprost Latanoprost Travoprost Total
Number of patients 1464 4994 1415 7873 P value*
% or mean (SD)
Female 56% 57% 54% 57% 0.129
Age 62.8 (11.8) 63.7 (12.3) 62.0 (11.8) 63.2 (12.1) < 0.001
Age group 40 to 54 26% 26% 29% 26% < 0.001
55 to 64 35% 31% 31% 32%
65 to 74 20% 21% 23% 21%
75+ 20% 23% 17% 21%
Ocular hypertension
† 36% 44% 39% 41% < 0.001
*Significance from chi-square test (%) or F test (mean). Comparison is between bimatoprost, latanoprost, and travoprost.
†Patients were identified with ocular hypertension if they had a medical service with any of these ICD-9 diagnostic codes in the 180 days before/on the index
date: 365.00 (preglaucoma), 365.01 (open-angle glaucoma with borderline findings), or 365.04 (ocular hypertension).
ICD-9 = International Classification of Diseases, Ninth Revision; SD = standard deviation.
Table 3 Persistence and days covered estimates
Method of imputing days supply Bimatoprost Latanoprost Travoprost Total P value*
No exclusions applied due to early failure or changes in therapy (base model)
% or mean (SD)
Medication possession
Unadjusted days supply 23% 31% 23% 28% < 0.001
2.0-2.1 Variable Factor
† 43% 50% 39% 47% < 0.001
2.0 Constant Factor/45
Minimum
3 43% 52% 41% 48% < 0.001
Days covered
Unadjusted days supply 119 (80) 141 (89) 108 (76) 131 (86) < 0.001
2.0-2.1 Variable Factor
† 218 (115) 239 (118) 197 (116) 228 (118) < 0.001
2.0 Constant Factor/45
Minimum
‡ 220 (113) 249 (115) 209 (114) 236 (116) < 0.001
Exclusions applied due to early failure or changes in therapy (alternative model)
% or mean (SD)
Medication possession
Unadjusted days supply 34% 44% 35% 41% < 0.001
2.0-2.1 Variable Factor
† 60% 66% 56% 64% < 0.001
2.0 Constant Factor/45
Minimum
‡ 60% 67% 58% 65% < 0.001
Days covered
Unadjusted days supply 183 (78) 198 (78) 167 (73) 191 (78) < 0.001
2.0-2.1 Variable Factor
† 294 (83) 305 (79) 280 (88) 299 (82) < 0.001
2.0 Constant Factor/45
Minimum
‡ 294 (82) 310 (75) 287 (83) 304 (78) < 0.001
*Significance from chi-square test (%) or F test (mean). Comparison is between bimatoprost, latanoprost, and travoprost.
†Imputed days supply is unadjusted days supply multiplied by 2.0 (latanoprost, travoprost) or 2.1 (bimatoprost).
‡Imputed days supply is unadjusted days supply multiplied by 2.0 (all prostaglandins), with a minimum imputed estimate of 45 days.
SD = standard deviation.
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justed days supply estimate. This rose to 228 and 236
days covered when the two other methods of imputation
were applied. Days covered varied significantly (p ≤
0.001) by therapy. Bimatoprost patients had higher days
of therapy than travoprost users, ranging from 11 to 21
days. However, latanoprost users had the highest num-
ber of days covered, ranging from 21 to 29 days higher
than that found for bimatoprost users.
“Early failures” (those subjects who did not refill their
prescription within 90 days of starting therapy)
accounted for 45 to 63% of the total patient cohort,
depending on the days supply imputation method
applied. When “early failures” were excluded from the
analysis, medication possession among all therapies
combined rose by a factor of 1.35 to 1.46 times greater
than in the base model (Table 3). Exclusion of “early
failures” caused days covered to similarly increase in
magnitude by a factor of 1.29 to 1.46 compared to the
base model. Differences among agents in the alternative
model were still significant.
When adjusted for covariates (Table 4), compared to
the reference latanoprost, the odds of achieving medica-
tion possession at first year’s end were 26 to 34% lower
for bimatoprost and 34 to 36% lower for travoprost
(p < 0.001 across each imputation; Table 4). Bimato-
prost had a somewhat higher odds of achieving medica-
t i o np o s s e s s i o nt h a nt r a v o p r o s tw h e nd a y ss u p p l yw a s
imputed, but this difference was significant (p = 0.048)
only for the imputation method “2.0-2.1 Variable Fac-
tor.” Patients in age cohorts 55 years of age and older
consistently had a higher odds of achieving medication
at day 358 compared to the reference 40 to 54 years
cohort, though this was significant for only some of the
days supply imputation method/patient age combina-
tions. Medication possession levels appeared to peak at
65 to 74 years and then decline for patients 75 years
and older. Having an ocular hypertension diagnosis had
no significant linear association with medication posses-
sion for any of the three days supply estimation
methods.
Results from the linear regression analysis for days
c o v e r e d( T a b l e4 )s h o w e ds i m i l a rf i n d i n g s .I nt h i s
adjusted model, days covered on therapy during the first
therapy year were 21 to 29 days lower for bimatoprost
and 33 to 42 days lower for travoprost (p ≤ 0.001 for all
comparisons) when compared to the reference latano-
prost. Bimatoprost had 11 to 21 greater days covered on
therapy than travoprost (p < 0.001 to 0.013). Higher
days covered for the over-55 cohorts compared to the
Table 4 Regression analyses of persistence and days coverage on index drug
Method of imputing days supply
Unadjusted 2.0-2.1 variable factor
† 2.0 Constant Factor
45 Minimum
‡
Variable* Odds
ratio
P value Odds
ratio
P value Odds ratio P value
Logistic regression of persistence on index drug
Bimatoprost 0.66 < 0.001 0.74 < 0.001 0.71 < 0.001
Travoprost 0.66 < 0.001 0.64 < 0.001 0.66 < 0.001
Female 0.99 0.889 0.97 0.545 0.96 0.423
Age 55 to 64 years 1.12 0.088 1.19 0.003 1.17 0.010
Age 65 to 74 years 1.21 0.009 1.27 < 0.001 1.24 0.001
Age 75+ years 1.10 0.204 1.14 0.057 1.16 0.025
Ocular hypertension 0.99 0.886 1.00 0.920 1.00 0.933
Linear regression of days coverage on index drug
Coefficient P value Coefficient P value Coefficient P value
Bimatoprost -21.60 < 0.001 -21.03 < 0.001 -28.85 < 0.001
Travoprost -32.84 < 0.001 -42.11 < 0.001 -39.44 < 0.001
Female 0.33 0.866 -0.56 0.833 -0.42 0.873
Age 55 to 64 years 12.67 < 0.001 17.17 < 0.001 16.21 < 0.001
Age 65 to 74 years 22.40 < 0.001 26.50 < 0.001 26.09 < 0.001
Age 75+ years 10.87 < 0.001 11.18 0.004 14.49 < 0.001
Ocular hypertension 2.31 0.241 -0.01 0.997 -0.17 0.950
Intercept 128.94 < 0.001 226.28 < 0.001 235.24 < 0.001
*Reference case is latanoprost as index drug; male; age 40 to 54 years; diagnostic-coded medical visit for preglaucoma or ocular hypertension during 180-day
preindex period.
†Imputed days supply is unadjusted days supply multiplied by 2.0 (latanoprost, travoprost) or 2.1 (bimatoprost).
‡Imputed days supply is unadjusted days supply multiplied by 2.0 (all prostaglandins), with a minimum imputed estimate of 45 days.
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isons (p < 0.001 for all). Again, days covered levels
appeared to peak at 65 to 74 years and then decline for
patients 75 years and older. As with medication posses-
sion, ocular hypertension had no significant linear asso-
ciation with days covered for any of the three days
supply estimation methods.
Discussion
A failure of even a minority of patients to achieve opti-
mal persistence for the progressive and often asympto-
matic disease of glaucoma can have important health
consequences. Our study of treatment-naive patients
dispensed bimatoprost, latanoprost, or travoprost
showed that 1-year persistence is less than optimal for
many patients who are new to prostaglandin therapy.
Even the most liberal methods for estimating days sup-
ply from the prescription claim (2.0-2.1 Variable Factor
and 2.0 Constant Factor/45 Minimum) showed that only
47 to 48% of patients had medication possession at 1
year from the start of therapy across treatments. Simi-
larly, when days covered was expressed as a ratio with
the 358-day follow-up period, these more liberal esti-
mates of days supply showed that patients had days cov-
ered with prostaglandins for only 64% (228/358) to 66%
(236/358) of the days in the first follow-up year. Of
these two persistence measures, days covered on therapy
may be a more reliable measure of continued therapy
usage than medication possession at a fixed point in
time since the former includes all prescription claims in
the first therapy year while the latter assesses only the
expected therapy coverage delivered by the last prescrip-
tion fill within the first therapy year.
A recent analysis by Lee and associates [24] evaluated
persistence across all prostaglandin agents using a gap
analysis methodology in which periods of 45, 60, and
120 days were permitted between fills before a gap in
therapy was identified. Using these assumptions, 11%,
29%, and 78% of patients, respectively, had no gaps in
therapy, and 33%, 53%, and 87%, respectively, had 30
days or fewer off therapy annually. In contrast to our
suboptimal findings for prostaglandin persistence, this
analysis found that only a minority of patients receiving
prostaglandins generally experienced gaps in therapy
over the course of a year. However, in that study,
patients were not required to be new to prostaglandin
therapy and were required, for inclusion, to have
received a refill of the same prostaglandin within 1 year
after the index fill. As found in the current analysis,
exclusion of subjects from analysis who failed to refill
their initial prostaglandin would remove a substantial
number of potential subjects (45 to 63% of the total
sample in our study) and cause persistence rates to
appear much higher than otherwise. Lack of persistence
among a large and important group of subjects is thus
ignored; such a protocol would “essentially exclud [e]
patients who discontinued therapy for reasons such as
lack of efficacy or side effects” [28].
Early failure as a screening tool for lack of persistence
Early failures could be related to any of a variety factors,
e.g., adverse effects, switching of agents, use of medica-
tion samples, cost. Since we found that excluding “early
failures” strongly improved persistence rates for the
retained sample, we conducted an unplanned follow-up
analysis to evaluate whether a simple “early failure” test
could be used as a practical tool to screen patients who
were likely to be nonpersistent. First, we coded each
patient as being an early failure (ie, failed to refill within
90 days) or not and then determined whether he or she
had medication possession at 358 days and, separately,
whether he or she achieved at least 270 days covered
(ie, 75% coverage throughout the year).
Results indicated modest sensitivity (53 to 70%) and
specificity (63 to 70%) of this “early failure” rule for pre-
dicting medication possession and days covered when
patients receiving any quantity of therapy on the index
date were included (Table 5). However, when initial fills
on the index date were limited to single bottles of the
smallest quantity available, 2.5 mL, which was dispensed
for 68% of patients studied, sensitivity declined some-
what but specificity improved considerably, especially
when estimating whether patients had achieved ≥ 270
days covered (specificity ranged from 90 to 99%). Thus,
evidence of the utility of this test was greatest for ruling
in or identifying those who are especially unlikely to
achieve at least 75% coverage of days supply throughout
the year for those patients who started therapy with sin-
gle fills of 2.5 mL bottles and did not refill within 90
days. The rule-out converse, predicting whether a
patient who actually does refill within 90 days is likely
to successfully complete at least 75% days coverage over
the year, is much less certain from this test. When com-
pared among prostaglandins, these “early failure” rates
for single fills of 2.5 mL bottles were 47% for bimato-
prost, 37% for latanoprost, and 49% for travoprost (p <
0.001, chi-square). Thus, these findings roughly parallel
the pattern of inter-prostaglandin comparisons for per-
sistence shown in Table 3.
In this study, we relied on claims data to identify
refills. Ophthalmologists are unlikely to have access to
such data but would need to rely on patient self-reports
regarding refill history. Patient self-reports regarding
compliance or persistence should be interpreted cau-
tiously [33]. Still, if a patient query tool could be devel-
oped that was largely accurate for revealing refill history
early in therapy, it might serve well as a screening tool
to identify patients who are unlikely to achieve
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glandin agent and require encouragement towards per-
sistence or a physician-directed change in therapy.
Further, such a tool could be used to reinforce persis-
tence through repeated administration by the ophthal-
mologist over the cycle of follow-up visits needed to
establish intraocular pressure control.
Comparisons among prostaglandin analogues
Regression models strongly support a persistence advan-
tage for latanoprost compared to bimatoprost and travo-
prost, even after adjusting for differences in covariates.
Similar findings favouring for latanoprost were found in
an earlier study [20] that used a survival analysis metho-
dology: patients treated with bimatoprost and travoprost
were 38 and 36% more likely to discontinue therapy,
respectively, when compared to latanoprost users (p <
0.001 for each comparison). In this earlier work [20],
authors suggested differences in rates of hyperemia
among these three agents as a potential explanation for
differences in persistence. In contrast, Wilensky and
associates [27] found that when “early failures” were
excluded from analysis, latanoprost users had 10 fewer
days of adherent therapy compared to bimatoprost (p <
0.05) with no significant difference between bimatoprost
and travoprost users.
We expected that patients with a medical visit coded
f o ro c u l a rh y p e r t e n s i o n / p r eglaucoma would have lower
medication possession and days covered than the
remaining patients. Nordstrom and associates [23]
found evidence of a modest effect (odds ratio = 0.92, p
< 0.05) in this direction in their comparison of persis-
tence by therapeutic class of ocular hypotensives used.
We presumed that glaucoma suspects would be more
likely to discontinue therapy than patients with a glau-
coma diagnosis. However, neither regression model
showed evidence of such a relationship. With regard to
age, results suggest that persistence improves with age
b u tt h a ti m p r o v e m e n tp e a k sa ta g e s6 5t o7 4a n d
declines thereafter.
Further Research Needed
A l t h o u g hi nt h ec u r r e n ts t u d yw eh a v ef o c u s e do na
specific dimension of adherence, namely estimation
techniques, further research is needed regarding the
scope of persistence problems in glaucoma, comparisons
of persistence rates among agents and patient groups,
the link between persistence and patient outcomes, and
evaluation of effective methods to improve persistence
among patients being treated for glaucoma. For
instance, we have learned from more extensive studies
of other therapeutic classes, such as statins, that persis-
tence is generally poor [34], that differences in persis-
tence likely exist among agents used to treat target
conditions [34,35], that high adherence is related to
worsened medical outcomes, such as development of
congestive heart failure [36], and that health provider
interventions can be shown to improve adherence to
statins [37]. In addition to exploring alternate methods
for assessing adherence, such as electronic monitoring,
further research should explore methods of improving
persistence and adherence. To date, little empirical
research has evaluated the impact of educational or
reminder interventions to improve persistence and
adherence of glaucoma therapy.
Limitations and strengths
This study has a number of limitations. First, as is com-
mon to all claims-based assessments, incomplete claims
data (eg, out-of-pocket purchases, use of medication
samples) could have influenced findings. Second, there
is no “gold standard” for estimating days supply from
prescription claim records, particularly if multiple sizes
or more than one bottle of medication are dispensed in
a fill, so we relied on an assessment of days supply
through a sensitivity analysis approach. Third, as Fiscella
Table 5 Sensitivity/specificity of 90 days/persistence
Any quantity fills Single bottle gills of 2.5 mL
Method of imputing days supply Sensitivity Specificity Sensitivity Specificity
Medication possession
Unadjusted days supply 56% 63% 47% 79%
2.0-2.1 Variable Factor* 60% 60% 53% 77%
2.0 Constant Factor/45
Minimum
† 61% 60% 54% 77%
Days covered
Unadjusted days supply 53% 68% 43% 99%
2.0-2.1 Variable Factor* 67% 69% 61% 90%
2.0 Constant Factor/45
Minimum
† 70% 70% 65% 90%
*Imputed days supply is unadjusted days supply multiplied by 2.0 (latanoprost, travoprost) or 2.1 (bimatoprost).
†Imputed days supply is unadjusted days supply multiplied by 2.0 (all prostaglandins), with a minimum imputed estimate of 45 days.
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Page 7 of 9and associates [32] and Mick and associates [31] have
shown, the number of drops available in 2.5 mL bottles
of bimatoprost exceeds those available in the latanoprost
and travoprost bottles due to overfill. The 2.1 (bimato-
prost) vs 2.0 (latanoprost and travoprost) adjustment
factor used in the days supply imputation “2.0-2.1 Vari-
able Factor” may not have adequately captured the effect
of this difference. Further, it is possible that due to dif-
ferences in overfill some patients using certain prosta-
glandin products might have either delayed refills due to
the “extra” amount of drug available at months’ end due
to overfill, or might have exhausted their drug supply
before months’ end and chosen not to refill until the
following month, when they would have become eligible
for refills under terms of their pharmacy insurance cov-
erage. Fourth, several adjustments for differences among
prostaglandin therapy cohorts were made in regression
models; factors unavailable in a claims database, such as
baseline intraocular pressure or human difficulty in
applying a single daily drop to each eye, may have influ-
enced findings but are unavailable in a claims database.
Fifth, “days covered” as an adherence measure differs
from “coverage” in a pharmacologic sense, since the lat-
ter more fully considers the dose-response relationships
that may vary among patients and across pharma-
cotherapies. Finally, possession of the drug or an ade-
quate days supply derived from initial fills and refill data
does not directly address compliance behavior (following
administration instruction s )s i n c eap a t i e n tm a yn o t
always properly use the medication while it is in his/her
possession. A patient may appear to be persistent or
adherent using the methods we applied, yet inconsistent
dosing schedules or administration of drops that miss
the eye, as has been documented in some studies
[38,39], may mean that some patients are not consis-
tently receiving reliable coverage from the prescribed
prostaglandins to effectively achieve consistent intraocu-
lar pressure control. Use of an electronic monitoring
method may provide a more accurate alternative to
pharmacy dispensing data and can yield further insight
into compliance behavior. When using electronic moni-
toring for assessing adherence of antihypertensive ther-
apy in Phase IV clinical trials, Vrijens et al. [40] showed
that 10% of all scheduled doses were omitted by sub-
jects: 42% of these were of a single day’s dose, whereas
43% were part of a sequence of several days (i.e. “drug
“holidays”). In glaucoma research, Robin et al. [41] used
electronic monitoring of topical ocular hypotensives to
capture a breadth of measures not possible with simple
observations of prescription fills, including dosing errors,
coverage as measured by daily adherence to scheduled
times of administration, intervals or gaps between doses,
and percent of doses actually taken.
This study also had a number of strengths. The natur-
alistic setting described by the claims data and the large
number of patients supported the generalisability of
findings and provided statistical power. The methods
used to assess persistence are based on concepts (medi-
cation possession and days covered) that have been eval-
uated for many other medical conditions.
Conclusions
Our findings strongly suggest that persistence with ocu-
lar prostaglandin therapy remains a problem for many
patients and should be a focus of educational efforts by
ophthalmologists. This problem was not apparent in
some earlier persistence studies since excluding patients
from analyses based on postindex experience would be
expected to overestimate persistence rates. In general,
latanoprost users had greater odds of achieving medica-
tion possession and more days covered during the first
therapy year than those prescribed bimatoprost or travo-
p r o s t ,s u g g e s t i n gt h a tc h o i c eo ft h e r a p ym a yb ea n
important consideration to improve persistence.
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